# Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

> **NCT00126438** · PHASE3 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 515 (actual)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** 123I-mIBG (meta-iodobenzylguanidine)

## Key facts

- **NCT ID:** NCT00126438
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126438, "Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00126438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*